Article

Personalised genetic management of CML

2016-01-01

Abstract excerpt

Although RT-qPCR is the recommended method for monitoring responses to TKI therapy, it might not be the best assay for patients with deep responses considered for treatment discontinuation. The current consensus is that therapy discontinuation is followed by relapse in at least 50% of patients and that persisting LSCs with low BCRABL1 expression or quiescent LSC with no BCR-ABL1 expression are the source of the re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e03ee491-4050-54f2-8f91-b17f8b4590d9
DOI: 10.25560/56367

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Personalised genetic management of CMLDOI 10.25560/56367Read

Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic ApproachesSemantic proximity Read

Beyond BCR::ABL1—The Role of Genomic Analyses in the Management of CMLSemantic proximity Read

Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?Semantic proximity Read

Digital PCR for BCR‐ABL1 Quantification in CML: Current Applications in Clinical PracticeSemantic proximity Read

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuationSemantic proximity Read

Targeted CML therapy: controlling drug resistance, seeking cureSemantic proximity Read

Monitoring disease response to tyrosine kinase inhibitor therapy in CML.Semantic proximity Read

Molecular monitoring in CML and the prospects for treatment-free remissions.Semantic proximity Read

Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation.Semantic proximity Read

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.Semantic proximity Read

Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.Semantic proximity Read

Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)Semantic proximity Read